Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $2 | $2 |
| - Cash | $1 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 142.4% | 5.1% | 5.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 78.5% | 93.9% | 89.3% | 93.4% |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 129.2% | 43.9% | -89.4% | -69.3% |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 101.6% | 10.2% | -93.6% | -72.6% |
| EPS Diluted | 5.68 | 0.24 | -2.21 | -1.64 |
| % Growth | 2,266.7% | 110.9% | -34.8% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |